Table 3. Competing Risks Analysis for Waitlist Mortality.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| SHR | 95% CI | P | SHR | 95% CI | P | |
| Age per Year | 1.03 | 1.00 – 1.06 | 0.03 | |||
| Female Sex | 0.96 | 0.62 – 1.51 | 0.87 | |||
| Autoimmune1 | 1.16 | 0.67 – 2.02 | 0.60 | |||
| NASH | 2.27 | 1.34 – 3.84 | 0.002 | 2.24 | 1.33 – 3.78 | 0.003 |
| Refractory Ascites | 1.30 | 0.75 – 2.24 | 0.35 | |||
| Any Hepatic Encephalopathy | 1.55 | 0.94 – 2.57 | 0.09 | |||
| Hypertension | 1.02 | 0.65 – 1.61 | 0.93 | |||
| Diabetes Mellitus | 1.18 | 0.74 – 1.90 | 0.48 | |||
| Baseline Creatinine per 1 mg/dL | 1.60 | 1.17 – 2.20 | 0.004 | 1.62 | 1.17 – 2.25 | 0.004 |
| Delta Creatinine per 1 mg/dL | 1.41 | 1.21 – 1.64 | <0.001 | |||
| Persistent AKI | 1.72 | 0.84 – 3.50 | 0.14 | |||
| MELD-Na per 1 point | 1.05 | 1.01 – 1.09 | 0.01 | |||
| Child Pugh Score | 1.16 | 1.03 – 1.31 | 0.01 | |||
1
Combined Autoimmune Hepatitis, Primary Sclerosing Cholangitis, and Primary Biliary Cholangitis; Hepatitis C (HCV); Non-Alcoholic Steatohepatitis (NASH); Hepatitis B (HBV); Sodium (Na); International Normalized Ratio (INR); Model for End-Stage Liver Disease with Serum Sodium (MELDNa)